Disease · MONDO_0006502
Trials249
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 14 more are not shown, since the checks do not confirm them.
1 to 20 of 249
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02509078 | Reevaluation Of Systemic Early Neuromuscular Blockade | Phase 3 | 1,008 | 2019-08-13 | Acute Respiratory Distress Syndrome | CISATRACURIUM BESYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT00979121 | Statins for Acutely Injured Lungs From Sepsis | Phase 3 | 745 | 2014-10-03 | Sepsis, Acute Lung Injury | ROSUVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT04291508 | Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery | Phase 2 | 488 | 2024-09-27 | Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis | ACETAMINOPHEN | Its record names the disease | ClinicalTrials.gov |
| NCT04843761 | ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 | Phase 3 | 473 | 2025-10-24 | Covid19 | AVIPTADIL, REMDESIVIR | Its record names the disease | ClinicalTrials.gov |
| NCT04478071 | Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) | Phase 2 | 448 | 2025-03-26 | Acute Respiratory Distress Syndrome, Coronavirus Infection | VADADUSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT04817332 | STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19 | Phase 3 | 406 | 2023-08-22 | Covid19 | BRENSOCATIB | Its record names the disease | ClinicalTrials.gov |
| NCT02622724 | Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) | Phase 3 | 301 | 2020-03-30 | Respiratory Distress Syndrome, Adult | INTERFERON BETA-1A | Its record names the disease | ClinicalTrials.gov |
| NCT00434993 | Drug Study of Albuterol to Treat Acute Lung Injury | Phase 2/3 | 282 | 2013-07-15 | Respiratory Distress Syndrome, Adult | ALBUTEROL SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT04351243 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | Phase 2 | 227 | 2021-12-10 | COVID-19 | GIMSILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02636868 | The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age | Phase 2 | 221 | 2021-04-23 | Respiratory Distress Syndrome | LUCINACTANT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04377620 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | Phase 3 | 211 | 2022-01-19 | COVID-19 | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04369469 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | Phase 3 | 202 | 2022-05-24 | COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral | RAVULIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04756128 | Impact of Colchicine and Low-dose Naltrexone on COVID-19 | Phase 2 | 142 | 2023-07-25 | Covid19 | COLCHICINE, NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT00201409 | A Randomized Trial of GM-CSF in Patients With ALI/ARDS | Phase 2 | 132 | 2015-04-27 | Respiratory Distress Syndrome, Adult | REGRAMOSTIM | Its record names the disease | ClinicalTrials.gov |
| NCT00215553 | KL₄Surfactant Treatment in Patients With ARDS | Phase 2 | 124 | 2012-04-27 | Acute Respiratory Distress Syndrome | LUCINACTANT | Its record names the disease | ClinicalTrials.gov |
| NCT04640194 | A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19 | Phase 2/3 | 104 | 2024-03-07 | Acute Respiratory Distress Syndrome | ALTEPLASE | Its record names the disease | ClinicalTrials.gov |
| NCT04750278 | A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19 | Phase 2/3 | 90 | 2024-01-05 | Severe to Critical COVID 19 With Associated ARDS | ADERAMASTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01709409 | A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants | Phase 3 | 88 | 2017-10-25 | Respiratory Distress Syndrome | PORACTANT ALFA | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04412057 | Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury | Phase 2 | 88 | 2022-03-04 | COVID-19 Pneumonia, Acute Lung Injury, ARDS | QUISOVALIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02074059 | Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates | Phase 2 | 80 | 2017-04-21 | Respiratory Distress Syndrome | LUCINACTANT | Open Targets' reading of its record | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006502/trials